How does ondansetron prevent chemotherapy-induced nausea and vomiting (CINV)?
Ondansetron prevents chemotherapy-induced nausea and vomiting mainly by blocking serotonin signaling in the gut and brain. When chemotherapy is given, some treatments damage the lining of the gastrointestinal tract, which triggers release of serotonin (5-HT). That serotonin activates 5-HT3 receptors on sensory nerves that carry nausea signals to the vomiting center in the brainstem. Ondansetron is a selective 5-HT3 (serotonin type 3) receptor antagonist, so it reduces the downstream signaling that would otherwise trigger nausea and vomiting [1].
What role do 5‑HT3 receptors play in nausea from chemotherapy?
5-HT3 receptors are located both in the gastrointestinal tract (on nerve endings that detect serotonin release) and in the central nervous system (including areas involved in triggering vomiting). By blocking these receptors, ondansetron interrupts the pathway from chemotherapy-triggered serotonin release to the brain’s emetic circuitry, which lowers both the intensity and likelihood of CINV [1].
Does ondansetron work for both early and delayed CINV?
Ondansetron is most commonly used to prevent early CINV (often occurring within the first 24 hours after chemotherapy) because the serotonin surge after chemotherapy is a major driver of early symptoms. Clinical regimens often adjust supportive meds depending on whether nausea is early, delayed, or both; for delayed CINV, additional mechanisms (like other neurotransmitters and inflammatory signaling) may be targeted with other drugs rather than relying on ondansetron alone [1].
Why do patients often take ondansetron before chemotherapy?
Ondansetron is typically given before or around the time of chemotherapy because it needs to be present to block the serotonin-driven signaling that starts soon after chemo exposure. If serotonin release and 5-HT3 receptor activation happen early, starting ondansetron ahead of time helps prevent the nausea/vomiting cascade from fully developing [1].
What ondansetron does not do (and why other meds may be added)
Because ondansetron targets only the 5-HT3 pathway, it may not fully control delayed CINV for everyone. That is why many oncology supportive-care regimens combine it with other agents that work through different mechanisms (for example, drugs that block NK1 receptors or reduce substance P signaling) to cover additional pathways involved in later or more persistent symptoms [1].
Sources
- NCBI Bookshelf, StatPearls: Ondansetron (mechanism of action and 5‑HT3 receptor blockade related to nausea/vomiting). https://www.ncbi.nlm.nih.gov/books/